nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Topotecan—ovarian cancer	0.168	0.361	CbGbCtD
Leflunomide—ABCG2—Paclitaxel—ovarian cancer	0.0833	0.179	CbGbCtD
Leflunomide—ABCG2—Carboplatin—ovarian cancer	0.0784	0.168	CbGbCtD
Leflunomide—ABCG2—Docetaxel—ovarian cancer	0.0602	0.129	CbGbCtD
Leflunomide—ABCG2—Doxorubicin—ovarian cancer	0.0449	0.0963	CbGbCtD
Leflunomide—CYP2C9—Paclitaxel—ovarian cancer	0.0309	0.0664	CbGbCtD
Leflunomide—DHODH—myometrium—ovarian cancer	0.00811	0.0838	CbGeAlD
Leflunomide—DHODH—gonad—ovarian cancer	0.0053	0.0547	CbGeAlD
Leflunomide—PTK2B—embryo—ovarian cancer	0.00494	0.0511	CbGeAlD
Leflunomide—DHODH—female reproductive system—ovarian cancer	0.00473	0.0489	CbGeAlD
Leflunomide—DHODH—female gonad—ovarian cancer	0.0043	0.0445	CbGeAlD
Leflunomide—AHR—myometrium—ovarian cancer	0.00423	0.0436	CbGeAlD
Leflunomide—DHODH—testis—ovarian cancer	0.00382	0.0394	CbGeAlD
Leflunomide—PTK2B—decidua—ovarian cancer	0.00381	0.0394	CbGeAlD
Leflunomide—PTK2B—gonad—ovarian cancer	0.00336	0.0347	CbGeAlD
Leflunomide—AHR—uterine cervix—ovarian cancer	0.00329	0.034	CbGeAlD
Leflunomide—AHR—decidua—ovarian cancer	0.00313	0.0324	CbGeAlD
Leflunomide—PTK2B—female reproductive system—ovarian cancer	0.003	0.031	CbGeAlD
Leflunomide—AHR—endometrium—ovarian cancer	0.00297	0.0307	CbGeAlD
Leflunomide—PTK2B—bone marrow—ovarian cancer	0.00283	0.0292	CbGeAlD
Leflunomide—DHODH—lymph node—ovarian cancer	0.00277	0.0286	CbGeAlD
Leflunomide—AHR—uterus—ovarian cancer	0.00274	0.0283	CbGeAlD
Leflunomide—PTK2B—female gonad—ovarian cancer	0.00273	0.0282	CbGeAlD
Leflunomide—PTK2B—vagina—ovarian cancer	0.00271	0.028	CbGeAlD
Leflunomide—AHR—female reproductive system—ovarian cancer	0.00246	0.0254	CbGeAlD
Leflunomide—PTK2B—testis—ovarian cancer	0.00242	0.025	CbGeAlD
Leflunomide—AHR—bone marrow—ovarian cancer	0.00233	0.024	CbGeAlD
Leflunomide—AHR—female gonad—ovarian cancer	0.00224	0.0232	CbGeAlD
Leflunomide—AHR—vagina—ovarian cancer	0.00223	0.023	CbGeAlD
Leflunomide—AHR—testis—ovarian cancer	0.00199	0.0205	CbGeAlD
Leflunomide—PTK2B—lymph node—ovarian cancer	0.00175	0.0181	CbGeAlD
Leflunomide—ABCG2—myometrium—ovarian cancer	0.00164	0.0169	CbGeAlD
Leflunomide—AHR—lymph node—ovarian cancer	0.00144	0.0149	CbGeAlD
Leflunomide—ABCG2—uterine cervix—ovarian cancer	0.00128	0.0132	CbGeAlD
Leflunomide—ABCG2—decidua—ovarian cancer	0.00122	0.0126	CbGeAlD
Leflunomide—ABCG2—endometrium—ovarian cancer	0.00115	0.0119	CbGeAlD
Leflunomide—ABCG2—uterus—ovarian cancer	0.00106	0.011	CbGeAlD
Leflunomide—ABCG2—bone marrow—ovarian cancer	0.000902	0.00932	CbGeAlD
Leflunomide—CYP2C9—female reproductive system—ovarian cancer	0.000873	0.00902	CbGeAlD
Leflunomide—ABCG2—female gonad—ovarian cancer	0.000869	0.00898	CbGeAlD
Leflunomide—ABCG2—vagina—ovarian cancer	0.000864	0.00893	CbGeAlD
Leflunomide—ABCG2—testis—ovarian cancer	0.000771	0.00797	CbGeAlD
Leflunomide—ABCG2—lymph node—ovarian cancer	0.000559	0.00577	CbGeAlD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—AKT1—ovarian cancer	0.00018	0.00114	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—PIK3CA—ovarian cancer	0.000179	0.00114	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CYP1B1—ovarian cancer	0.000179	0.00114	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—MAPK3—ovarian cancer	0.000179	0.00113	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—VEGFA—ovarian cancer	0.000179	0.00113	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—MAPK3—ovarian cancer	0.000178	0.00113	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—NRAS—ovarian cancer	0.000176	0.00112	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—ERBB2—ovarian cancer	0.000176	0.00112	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—CASP3—ovarian cancer	0.000176	0.00111	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—MTOR—ovarian cancer	0.000174	0.0011	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—ovarian cancer	0.000173	0.0011	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—DLC1—ovarian cancer	0.000173	0.0011	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—ovarian cancer	0.00017	0.00108	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—MAPK1—ovarian cancer	0.00017	0.00108	CbGpPWpGaD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.00017	0.00108	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—CTNNB1—ovarian cancer	0.000169	0.00107	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—MAPK1—ovarian cancer	0.000169	0.00107	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—MAPK3—ovarian cancer	0.000169	0.00107	CbGpPWpGaD
Leflunomide—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000168	0.00106	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	0.000167	0.00106	CbGpPWpGaD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000161	0.00102	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—KRAS—ovarian cancer	0.000161	0.00102	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—MAPK1—ovarian cancer	0.000161	0.00102	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—KRAS—ovarian cancer	0.00016	0.00101	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PPP2R1A—ovarian cancer	0.000159	0.00101	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—TP53—ovarian cancer	0.000157	0.000997	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—HRAS—ovarian cancer	0.000157	0.000996	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL6ST—ovarian cancer	0.000153	0.000967	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—KRAS—ovarian cancer	0.000152	0.000963	CbGpPWpGaD
Leflunomide—Hyperglycaemia—Epirubicin—ovarian cancer	0.000152	0.000543	CcSEcCtD
Leflunomide—Cough—Docetaxel—ovarian cancer	0.000152	0.000542	CcSEcCtD
Leflunomide—Angina pectoris—Doxorubicin—ovarian cancer	0.000152	0.000542	CcSEcCtD
Leflunomide—Insomnia—Paclitaxel—ovarian cancer	0.000151	0.000541	CcSEcCtD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ovarian cancer	0.000151	0.000959	CbGpPWpGaD
Leflunomide—Pneumonia—Epirubicin—ovarian cancer	0.000151	0.000539	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—PTEN—ovarian cancer	0.00015	0.000953	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—IL6—ovarian cancer	0.00015	0.000953	CbGpPWpGaD
Leflunomide—Paraesthesia—Paclitaxel—ovarian cancer	0.00015	0.000537	CcSEcCtD
Leflunomide—Hypertension—Docetaxel—ovarian cancer	0.00015	0.000536	CcSEcCtD
Leflunomide—Infestation NOS—Epirubicin—ovarian cancer	0.00015	0.000536	CcSEcCtD
Leflunomide—Infestation—Epirubicin—ovarian cancer	0.00015	0.000536	CcSEcCtD
Leflunomide—Bronchitis—Doxorubicin—ovarian cancer	0.00015	0.000535	CcSEcCtD
Leflunomide—Dyspnoea—Paclitaxel—ovarian cancer	0.000149	0.000533	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000149	0.000532	CcSEcCtD
Leflunomide—Myalgia—Docetaxel—ovarian cancer	0.000148	0.000529	CcSEcCtD
Leflunomide—Chest pain—Docetaxel—ovarian cancer	0.000148	0.000529	CcSEcCtD
Leflunomide—Arthralgia—Docetaxel—ovarian cancer	0.000148	0.000529	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—PIK3CA—ovarian cancer	0.000148	0.000937	CbGpPWpGaD
Leflunomide—Pancytopenia—Doxorubicin—ovarian cancer	0.000148	0.000528	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—STAT3—ovarian cancer	0.000148	0.000937	CbGpPWpGaD
Leflunomide—Nausea—Vinorelbine—ovarian cancer	0.000148	0.000528	CcSEcCtD
Leflunomide—DHODH—Metabolism—ABCB1—ovarian cancer	0.000148	0.000936	CbGpPWpGaD
Leflunomide—Renal failure—Epirubicin—ovarian cancer	0.000147	0.000527	CcSEcCtD
Leflunomide—Dyspepsia—Paclitaxel—ovarian cancer	0.000147	0.000527	CcSEcCtD
Leflunomide—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000147	0.000526	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000147	0.000525	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—PIK3CA—ovarian cancer	0.000147	0.00093	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—AKT1—ovarian cancer	0.000147	0.000929	CbGpPWpGaD
Leflunomide—Stomatitis—Epirubicin—ovarian cancer	0.000146	0.000523	CcSEcCtD
Leflunomide—Jaundice—Epirubicin—ovarian cancer	0.000146	0.000523	CcSEcCtD
Leflunomide—Urinary tract infection—Epirubicin—ovarian cancer	0.000146	0.000521	CcSEcCtD
Leflunomide—Conjunctivitis—Epirubicin—ovarian cancer	0.000146	0.000521	CcSEcCtD
Leflunomide—Neutropenia—Doxorubicin—ovarian cancer	0.000146	0.00052	CcSEcCtD
Leflunomide—Dysuria—Doxorubicin—ovarian cancer	0.000146	0.00052	CcSEcCtD
Leflunomide—Decreased appetite—Paclitaxel—ovarian cancer	0.000145	0.00052	CcSEcCtD
Leflunomide—DHODH—Metabolism—TYMS—ovarian cancer	0.000145	0.000919	CbGpPWpGaD
Leflunomide—Dry mouth—Docetaxel—ovarian cancer	0.000145	0.000517	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000145	0.000517	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000144	0.000516	CcSEcCtD
Leflunomide—Fatigue—Paclitaxel—ovarian cancer	0.000144	0.000516	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—IL6—ovarian cancer	0.000144	0.000913	CbGpPWpGaD
Leflunomide—Pollakiuria—Doxorubicin—ovarian cancer	0.000144	0.000514	CcSEcCtD
Leflunomide—Pain—Paclitaxel—ovarian cancer	0.000143	0.000512	CcSEcCtD
Leflunomide—Constipation—Paclitaxel—ovarian cancer	0.000143	0.000512	CcSEcCtD
Leflunomide—Haematuria—Epirubicin—ovarian cancer	0.000143	0.000511	CcSEcCtD
Leflunomide—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000142	0.000507	CcSEcCtD
Leflunomide—Anaphylactic shock—Docetaxel—ovarian cancer	0.000142	0.000507	CcSEcCtD
Leflunomide—Epistaxis—Epirubicin—ovarian cancer	0.000141	0.000506	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—MAPK3—ovarian cancer	0.000141	0.000895	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—BCL9—ovarian cancer	0.000141	0.000893	CbGpPWpGaD
Leflunomide—Infection—Docetaxel—ovarian cancer	0.000141	0.000504	CcSEcCtD
Leflunomide—Weight decreased—Doxorubicin—ovarian cancer	0.000141	0.000503	CcSEcCtD
Leflunomide—Sinusitis—Epirubicin—ovarian cancer	0.000141	0.000503	CcSEcCtD
Leflunomide—Hyperglycaemia—Doxorubicin—ovarian cancer	0.00014	0.000502	CcSEcCtD
Leflunomide—Agranulocytosis—Epirubicin—ovarian cancer	0.00014	0.0005	CcSEcCtD
Leflunomide—Pneumonia—Doxorubicin—ovarian cancer	0.00014	0.000499	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—PIK3CA—ovarian cancer	0.000139	0.000884	CbGpPWpGaD
Leflunomide—Nervous system disorder—Docetaxel—ovarian cancer	0.000139	0.000497	CcSEcCtD
Leflunomide—Thrombocytopenia—Docetaxel—ovarian cancer	0.000139	0.000496	CcSEcCtD
Leflunomide—Infestation—Doxorubicin—ovarian cancer	0.000139	0.000496	CcSEcCtD
Leflunomide—Infestation NOS—Doxorubicin—ovarian cancer	0.000139	0.000496	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—AKT1—ovarian cancer	0.000139	0.000879	CbGpPWpGaD
Leflunomide—Tachycardia—Docetaxel—ovarian cancer	0.000138	0.000495	CcSEcCtD
Leflunomide—Feeling abnormal—Paclitaxel—ovarian cancer	0.000138	0.000493	CcSEcCtD
Leflunomide—Skin disorder—Docetaxel—ovarian cancer	0.000138	0.000493	CcSEcCtD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000138	0.000873	CbGpPWpGaD
Leflunomide—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000138	0.000492	CcSEcCtD
Leflunomide—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000137	0.000489	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—HRAS—ovarian cancer	0.000137	0.000867	CbGpPWpGaD
Leflunomide—Renal failure—Doxorubicin—ovarian cancer	0.000136	0.000488	CcSEcCtD
Leflunomide—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000136	0.000486	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—HRAS—ovarian cancer	0.000136	0.00086	CbGpPWpGaD
Leflunomide—Haemoglobin—Epirubicin—ovarian cancer	0.000135	0.000484	CcSEcCtD
Leflunomide—Jaundice—Doxorubicin—ovarian cancer	0.000135	0.000484	CcSEcCtD
Leflunomide—Stomatitis—Doxorubicin—ovarian cancer	0.000135	0.000484	CcSEcCtD
Leflunomide—Anorexia—Docetaxel—ovarian cancer	0.000135	0.000483	CcSEcCtD
Leflunomide—PTK2B—Immune System—PVRL2—ovarian cancer	0.000135	0.000857	CbGpPWpGaD
Leflunomide—Rhinitis—Epirubicin—ovarian cancer	0.000135	0.000483	CcSEcCtD
Leflunomide—Urinary tract infection—Doxorubicin—ovarian cancer	0.000135	0.000482	CcSEcCtD
Leflunomide—Conjunctivitis—Doxorubicin—ovarian cancer	0.000135	0.000482	CcSEcCtD
Leflunomide—Hepatitis—Epirubicin—ovarian cancer	0.000135	0.000481	CcSEcCtD
Leflunomide—Haemorrhage—Epirubicin—ovarian cancer	0.000135	0.000481	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—STAT3—ovarian cancer	0.000134	0.000852	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—MAPK1—ovarian cancer	0.000134	0.000851	CbGpPWpGaD
Leflunomide—Pharyngitis—Epirubicin—ovarian cancer	0.000134	0.000478	CcSEcCtD
Leflunomide—Urinary tract disorder—Epirubicin—ovarian cancer	0.000133	0.000475	CcSEcCtD
Leflunomide—Urticaria—Paclitaxel—ovarian cancer	0.000133	0.000475	CcSEcCtD
Leflunomide—Oedema peripheral—Epirubicin—ovarian cancer	0.000133	0.000474	CcSEcCtD
Leflunomide—Hypotension—Docetaxel—ovarian cancer	0.000132	0.000474	CcSEcCtD
Leflunomide—Haematuria—Doxorubicin—ovarian cancer	0.000132	0.000473	CcSEcCtD
Leflunomide—Connective tissue disorder—Epirubicin—ovarian cancer	0.000132	0.000473	CcSEcCtD
Leflunomide—Body temperature increased—Paclitaxel—ovarian cancer	0.000132	0.000473	CcSEcCtD
Leflunomide—Abdominal pain—Paclitaxel—ovarian cancer	0.000132	0.000473	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.000132	0.000838	CbGpPWpGaD
Leflunomide—Urethral disorder—Epirubicin—ovarian cancer	0.000132	0.000472	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	0.000132	0.000837	CbGpPWpGaD
Leflunomide—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000131	0.000469	CcSEcCtD
Leflunomide—Epistaxis—Doxorubicin—ovarian cancer	0.000131	0.000468	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—IL6—ovarian cancer	0.000131	0.00083	CbGpPWpGaD
Leflunomide—Sinusitis—Doxorubicin—ovarian cancer	0.00013	0.000465	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—IL6—ovarian cancer	0.00013	0.000824	CbGpPWpGaD
Leflunomide—Agranulocytosis—Doxorubicin—ovarian cancer	0.000129	0.000463	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	0.000129	0.000821	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000129	0.000462	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—HRAS—ovarian cancer	0.000129	0.000818	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CD—ovarian cancer	0.000129	0.000817	CbGpPWpGaD
Leflunomide—Insomnia—Docetaxel—ovarian cancer	0.000128	0.000459	CcSEcCtD
Leflunomide—Paraesthesia—Docetaxel—ovarian cancer	0.000127	0.000455	CcSEcCtD
Leflunomide—Erythema multiforme—Epirubicin—ovarian cancer	0.000127	0.000455	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.000127	0.000803	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—PIK3CA—ovarian cancer	0.000126	0.000802	CbGpPWpGaD
Leflunomide—Dyspnoea—Docetaxel—ovarian cancer	0.000126	0.000452	CcSEcCtD
Leflunomide—Eye disorder—Epirubicin—ovarian cancer	0.000126	0.00045	CcSEcCtD
Leflunomide—Haemoglobin—Doxorubicin—ovarian cancer	0.000125	0.000448	CcSEcCtD
Leflunomide—Cardiac disorder—Epirubicin—ovarian cancer	0.000125	0.000447	CcSEcCtD
Leflunomide—Rhinitis—Doxorubicin—ovarian cancer	0.000125	0.000447	CcSEcCtD
Leflunomide—Dyspepsia—Docetaxel—ovarian cancer	0.000125	0.000446	CcSEcCtD
Leflunomide—Haemorrhage—Doxorubicin—ovarian cancer	0.000125	0.000445	CcSEcCtD
Leflunomide—Hepatitis—Doxorubicin—ovarian cancer	0.000125	0.000445	CcSEcCtD
Leflunomide—Pharyngitis—Doxorubicin—ovarian cancer	0.000124	0.000442	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—IL6—ovarian cancer	0.000124	0.000783	CbGpPWpGaD
Leflunomide—Decreased appetite—Docetaxel—ovarian cancer	0.000123	0.000441	CcSEcCtD
Leflunomide—Hypersensitivity—Paclitaxel—ovarian cancer	0.000123	0.000441	CcSEcCtD
Leflunomide—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000123	0.00044	CcSEcCtD
Leflunomide—Oedema peripheral—Doxorubicin—ovarian cancer	0.000123	0.000439	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000122	0.000438	CcSEcCtD
Leflunomide—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000122	0.000438	CcSEcCtD
Leflunomide—Fatigue—Docetaxel—ovarian cancer	0.000122	0.000437	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—MAPK1—ovarian cancer	0.000122	0.000775	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—EGFR—ovarian cancer	0.000122	0.000775	CbGpPWpGaD
Leflunomide—Urethral disorder—Doxorubicin—ovarian cancer	0.000122	0.000437	CcSEcCtD
Leflunomide—Immune system disorder—Epirubicin—ovarian cancer	0.000122	0.000435	CcSEcCtD
Leflunomide—Mediastinal disorder—Epirubicin—ovarian cancer	0.000121	0.000434	CcSEcCtD
Leflunomide—Constipation—Docetaxel—ovarian cancer	0.000121	0.000434	CcSEcCtD
Leflunomide—Pain—Docetaxel—ovarian cancer	0.000121	0.000434	CcSEcCtD
Leflunomide—Chills—Epirubicin—ovarian cancer	0.000121	0.000432	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—AKT1—ovarian cancer	0.000121	0.000765	CbGpPWpGaD
Leflunomide—Arrhythmia—Epirubicin—ovarian cancer	0.00012	0.00043	CcSEcCtD
Leflunomide—Asthenia—Paclitaxel—ovarian cancer	0.00012	0.000429	CcSEcCtD
Leflunomide—Alopecia—Epirubicin—ovarian cancer	0.000119	0.000425	CcSEcCtD
Leflunomide—Pruritus—Paclitaxel—ovarian cancer	0.000118	0.000423	CcSEcCtD
Leflunomide—Mental disorder—Epirubicin—ovarian cancer	0.000118	0.000422	CcSEcCtD
Leflunomide—Erythema multiforme—Doxorubicin—ovarian cancer	0.000118	0.000421	CcSEcCtD
Leflunomide—Malnutrition—Epirubicin—ovarian cancer	0.000117	0.000419	CcSEcCtD
Leflunomide—Feeling abnormal—Docetaxel—ovarian cancer	0.000117	0.000418	CcSEcCtD
Leflunomide—DHODH—Metabolism—CAV1—ovarian cancer	0.000117	0.00074	CbGpPWpGaD
Leflunomide—Eye disorder—Doxorubicin—ovarian cancer	0.000116	0.000416	CcSEcCtD
Leflunomide—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000116	0.000415	CcSEcCtD
Leflunomide—Cardiac disorder—Doxorubicin—ovarian cancer	0.000116	0.000413	CcSEcCtD
Leflunomide—Flatulence—Epirubicin—ovarian cancer	0.000115	0.000413	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—KRAS—ovarian cancer	0.000115	0.000732	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PARK2—ovarian cancer	0.000115	0.000732	CbGpPWpGaD
Leflunomide—Dysgeusia—Epirubicin—ovarian cancer	0.000115	0.00041	CcSEcCtD
Leflunomide—Diarrhoea—Paclitaxel—ovarian cancer	0.000114	0.000409	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—AKT1—ovarian cancer	0.000114	0.000723	CbGpPWpGaD
Leflunomide—Back pain—Epirubicin—ovarian cancer	0.000113	0.000405	CcSEcCtD
Leflunomide—Muscle spasms—Epirubicin—ovarian cancer	0.000113	0.000403	CcSEcCtD
Leflunomide—Immune system disorder—Doxorubicin—ovarian cancer	0.000112	0.000402	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CB—ovarian cancer	0.000112	0.000712	CbGpPWpGaD
Leflunomide—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000112	0.000401	CcSEcCtD
Leflunomide—Body temperature increased—Docetaxel—ovarian cancer	0.000112	0.000401	CcSEcCtD
Leflunomide—Abdominal pain—Docetaxel—ovarian cancer	0.000112	0.000401	CcSEcCtD
Leflunomide—Chills—Doxorubicin—ovarian cancer	0.000112	0.0004	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—DOK1—ovarian cancer	0.000111	0.000706	CbGpPWpGaD
Leflunomide—Arrhythmia—Doxorubicin—ovarian cancer	0.000111	0.000398	CcSEcCtD
Leflunomide—Dizziness—Paclitaxel—ovarian cancer	0.000111	0.000396	CcSEcCtD
Leflunomide—Vision blurred—Epirubicin—ovarian cancer	0.00011	0.000395	CcSEcCtD
Leflunomide—Alopecia—Doxorubicin—ovarian cancer	0.00011	0.000394	CcSEcCtD
Leflunomide—Mental disorder—Doxorubicin—ovarian cancer	0.000109	0.00039	CcSEcCtD
Leflunomide—Ill-defined disorder—Epirubicin—ovarian cancer	0.000109	0.000389	CcSEcCtD
Leflunomide—Malnutrition—Doxorubicin—ovarian cancer	0.000108	0.000388	CcSEcCtD
Leflunomide—Anaemia—Epirubicin—ovarian cancer	0.000108	0.000387	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—HRAS—ovarian cancer	0.000108	0.000684	CbGpPWpGaD
Leflunomide—Flatulence—Doxorubicin—ovarian cancer	0.000107	0.000382	CcSEcCtD
Leflunomide—DHODH—Metabolism—PIK3CG—ovarian cancer	0.000106	0.000674	CbGpPWpGaD
Leflunomide—Vomiting—Paclitaxel—ovarian cancer	0.000106	0.00038	CcSEcCtD
Leflunomide—Dysgeusia—Doxorubicin—ovarian cancer	0.000106	0.00038	CcSEcCtD
Leflunomide—Malaise—Epirubicin—ovarian cancer	0.000106	0.000378	CcSEcCtD
Leflunomide—Rash—Paclitaxel—ovarian cancer	0.000105	0.000377	CcSEcCtD
Leflunomide—Dermatitis—Paclitaxel—ovarian cancer	0.000105	0.000377	CcSEcCtD
Leflunomide—Vertigo—Epirubicin—ovarian cancer	0.000105	0.000376	CcSEcCtD
Leflunomide—Leukopenia—Epirubicin—ovarian cancer	0.000105	0.000375	CcSEcCtD
Leflunomide—Back pain—Doxorubicin—ovarian cancer	0.000105	0.000375	CcSEcCtD
Leflunomide—Headache—Paclitaxel—ovarian cancer	0.000105	0.000375	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—PPP1CC—ovarian cancer	0.000105	0.000664	CbGpPWpGaD
Leflunomide—Hypersensitivity—Docetaxel—ovarian cancer	0.000104	0.000374	CcSEcCtD
Leflunomide—Muscle spasms—Doxorubicin—ovarian cancer	0.000104	0.000373	CcSEcCtD
Leflunomide—Palpitations—Epirubicin—ovarian cancer	0.000104	0.00037	CcSEcCtD
Leflunomide—ABCG2—Metabolism—NME2—ovarian cancer	0.000103	0.000655	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL2—ovarian cancer	0.000103	0.000654	CbGpPWpGaD
Leflunomide—Cough—Epirubicin—ovarian cancer	0.000102	0.000366	CcSEcCtD
Leflunomide—Vision blurred—Doxorubicin—ovarian cancer	0.000102	0.000365	CcSEcCtD
Leflunomide—Asthenia—Docetaxel—ovarian cancer	0.000102	0.000364	CcSEcCtD
Leflunomide—PTK2B—Immune System—IKBKG—ovarian cancer	0.000101	0.000642	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EREG—ovarian cancer	0.000101	0.000642	CbGpPWpGaD
Leflunomide—Hypertension—Epirubicin—ovarian cancer	0.000101	0.000362	CcSEcCtD
Leflunomide—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000101	0.00036	CcSEcCtD
Leflunomide—Pruritus—Docetaxel—ovarian cancer	0.0001	0.000359	CcSEcCtD
Leflunomide—Anaemia—Doxorubicin—ovarian cancer	0.0001	0.000358	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	0.0001	0.000635	CbGpPWpGaD
Leflunomide—Myalgia—Epirubicin—ovarian cancer	9.98e-05	0.000357	CcSEcCtD
Leflunomide—Arthralgia—Epirubicin—ovarian cancer	9.98e-05	0.000357	CcSEcCtD
Leflunomide—Chest pain—Epirubicin—ovarian cancer	9.98e-05	0.000357	CcSEcCtD
Leflunomide—Anxiety—Epirubicin—ovarian cancer	9.94e-05	0.000356	CcSEcCtD
Leflunomide—Nausea—Paclitaxel—ovarian cancer	9.94e-05	0.000355	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	9.91e-05	0.000354	CcSEcCtD
Leflunomide—PTK2B—Immune System—SKP2—ovarian cancer	9.89e-05	0.000627	CbGpPWpGaD
Leflunomide—Discomfort—Epirubicin—ovarian cancer	9.86e-05	0.000352	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—HRAS—ovarian cancer	9.81e-05	0.000622	CbGpPWpGaD
Leflunomide—Malaise—Doxorubicin—ovarian cancer	9.78e-05	0.00035	CcSEcCtD
Leflunomide—Dry mouth—Epirubicin—ovarian cancer	9.76e-05	0.000349	CcSEcCtD
Leflunomide—Vertigo—Doxorubicin—ovarian cancer	9.74e-05	0.000348	CcSEcCtD
Leflunomide—Leukopenia—Doxorubicin—ovarian cancer	9.71e-05	0.000347	CcSEcCtD
Leflunomide—Diarrhoea—Docetaxel—ovarian cancer	9.7e-05	0.000347	CcSEcCtD
Leflunomide—Palpitations—Doxorubicin—ovarian cancer	9.58e-05	0.000343	CcSEcCtD
Leflunomide—Anaphylactic shock—Epirubicin—ovarian cancer	9.56e-05	0.000342	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—AKT1—ovarian cancer	9.52e-05	0.000604	CbGpPWpGaD
Leflunomide—Infection—Epirubicin—ovarian cancer	9.5e-05	0.00034	CcSEcCtD
Leflunomide—Cough—Doxorubicin—ovarian cancer	9.46e-05	0.000338	CcSEcCtD
Leflunomide—Nervous system disorder—Epirubicin—ovarian cancer	9.38e-05	0.000335	CcSEcCtD
Leflunomide—Dizziness—Docetaxel—ovarian cancer	9.38e-05	0.000335	CcSEcCtD
Leflunomide—Thrombocytopenia—Epirubicin—ovarian cancer	9.36e-05	0.000335	CcSEcCtD
Leflunomide—Hypertension—Doxorubicin—ovarian cancer	9.36e-05	0.000335	CcSEcCtD
Leflunomide—DHODH—Metabolism—PIK3CD—ovarian cancer	9.35e-05	0.000593	CbGpPWpGaD
Leflunomide—Tachycardia—Epirubicin—ovarian cancer	9.33e-05	0.000334	CcSEcCtD
Leflunomide—Skin disorder—Epirubicin—ovarian cancer	9.29e-05	0.000332	CcSEcCtD
Leflunomide—Hyperhidrosis—Epirubicin—ovarian cancer	9.25e-05	0.000331	CcSEcCtD
Leflunomide—Myalgia—Doxorubicin—ovarian cancer	9.23e-05	0.00033	CcSEcCtD
Leflunomide—Chest pain—Doxorubicin—ovarian cancer	9.23e-05	0.00033	CcSEcCtD
Leflunomide—Arthralgia—Doxorubicin—ovarian cancer	9.23e-05	0.00033	CcSEcCtD
Leflunomide—Anxiety—Doxorubicin—ovarian cancer	9.2e-05	0.000329	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	9.17e-05	0.000328	CcSEcCtD
Leflunomide—Discomfort—Doxorubicin—ovarian cancer	9.12e-05	0.000326	CcSEcCtD
Leflunomide—Anorexia—Epirubicin—ovarian cancer	9.12e-05	0.000326	CcSEcCtD
Leflunomide—Dry mouth—Doxorubicin—ovarian cancer	9.03e-05	0.000323	CcSEcCtD
Leflunomide—Vomiting—Docetaxel—ovarian cancer	9.01e-05	0.000322	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	8.97e-05	0.000569	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	8.97e-05	0.000569	CbGpPWpGaD
Leflunomide—Rash—Docetaxel—ovarian cancer	8.94e-05	0.00032	CcSEcCtD
Leflunomide—Hypotension—Epirubicin—ovarian cancer	8.94e-05	0.00032	CcSEcCtD
Leflunomide—Dermatitis—Docetaxel—ovarian cancer	8.93e-05	0.000319	CcSEcCtD
Leflunomide—Headache—Docetaxel—ovarian cancer	8.88e-05	0.000318	CcSEcCtD
Leflunomide—Anaphylactic shock—Doxorubicin—ovarian cancer	8.85e-05	0.000316	CcSEcCtD
Leflunomide—Infection—Doxorubicin—ovarian cancer	8.79e-05	0.000314	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	8.78e-05	0.000557	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Epirubicin—ovarian cancer	8.71e-05	0.000312	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—STAT3—ovarian cancer	8.68e-05	0.00055	CbGpPWpGaD
Leflunomide—Nervous system disorder—Doxorubicin—ovarian cancer	8.68e-05	0.00031	CcSEcCtD
Leflunomide—Thrombocytopenia—Doxorubicin—ovarian cancer	8.66e-05	0.00031	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—AKT1—ovarian cancer	8.66e-05	0.000549	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—NRAS—ovarian cancer	8.66e-05	0.000549	CbGpPWpGaD
Leflunomide—Insomnia—Epirubicin—ovarian cancer	8.65e-05	0.000309	CcSEcCtD
Leflunomide—Tachycardia—Doxorubicin—ovarian cancer	8.64e-05	0.000309	CcSEcCtD
Leflunomide—Skin disorder—Doxorubicin—ovarian cancer	8.59e-05	0.000307	CcSEcCtD
Leflunomide—Paraesthesia—Epirubicin—ovarian cancer	8.59e-05	0.000307	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	8.56e-05	0.000543	CbGpPWpGaD
Leflunomide—Hyperhidrosis—Doxorubicin—ovarian cancer	8.55e-05	0.000306	CcSEcCtD
Leflunomide—Dyspnoea—Epirubicin—ovarian cancer	8.53e-05	0.000305	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	8.44e-05	0.000535	CbGpPWpGaD
Leflunomide—Anorexia—Doxorubicin—ovarian cancer	8.43e-05	0.000302	CcSEcCtD
Leflunomide—Nausea—Docetaxel—ovarian cancer	8.42e-05	0.000301	CcSEcCtD
Leflunomide—Dyspepsia—Epirubicin—ovarian cancer	8.42e-05	0.000301	CcSEcCtD
Leflunomide—Decreased appetite—Epirubicin—ovarian cancer	8.31e-05	0.000297	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—MAPK3—ovarian cancer	8.29e-05	0.000526	CbGpPWpGaD
Leflunomide—Hypotension—Doxorubicin—ovarian cancer	8.27e-05	0.000296	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	8.26e-05	0.000524	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Epirubicin—ovarian cancer	8.26e-05	0.000295	CcSEcCtD
Leflunomide—Fatigue—Epirubicin—ovarian cancer	8.25e-05	0.000295	CcSEcCtD
Leflunomide—Pain—Epirubicin—ovarian cancer	8.18e-05	0.000292	CcSEcCtD
Leflunomide—Constipation—Epirubicin—ovarian cancer	8.18e-05	0.000292	CcSEcCtD
Leflunomide—DHODH—Metabolism—PIK3CB—ovarian cancer	8.15e-05	0.000517	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	8.06e-05	0.000288	CcSEcCtD
Leflunomide—Insomnia—Doxorubicin—ovarian cancer	8e-05	0.000286	CcSEcCtD
Leflunomide—Paraesthesia—Doxorubicin—ovarian cancer	7.95e-05	0.000284	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—HDAC6—ovarian cancer	7.93e-05	0.000503	CbGpPWpGaD
Leflunomide—Dyspnoea—Doxorubicin—ovarian cancer	7.89e-05	0.000282	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—MAPK1—ovarian cancer	7.89e-05	0.0005	CbGpPWpGaD
Leflunomide—Feeling abnormal—Epirubicin—ovarian cancer	7.88e-05	0.000282	CcSEcCtD
Leflunomide—Gastrointestinal pain—Epirubicin—ovarian cancer	7.82e-05	0.00028	CcSEcCtD
Leflunomide—Dyspepsia—Doxorubicin—ovarian cancer	7.79e-05	0.000279	CcSEcCtD
Leflunomide—Decreased appetite—Doxorubicin—ovarian cancer	7.69e-05	0.000275	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Doxorubicin—ovarian cancer	7.64e-05	0.000273	CcSEcCtD
Leflunomide—Fatigue—Doxorubicin—ovarian cancer	7.63e-05	0.000273	CcSEcCtD
Leflunomide—Urticaria—Epirubicin—ovarian cancer	7.6e-05	0.000272	CcSEcCtD
Leflunomide—Constipation—Doxorubicin—ovarian cancer	7.57e-05	0.000271	CcSEcCtD
Leflunomide—Pain—Doxorubicin—ovarian cancer	7.57e-05	0.000271	CcSEcCtD
Leflunomide—Body temperature increased—Epirubicin—ovarian cancer	7.56e-05	0.00027	CcSEcCtD
Leflunomide—Abdominal pain—Epirubicin—ovarian cancer	7.56e-05	0.00027	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	7.46e-05	0.000473	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—KRAS—ovarian cancer	7.45e-05	0.000472	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	7.37e-05	0.000467	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	7.32e-05	0.000464	CbGpPWpGaD
Leflunomide—Feeling abnormal—Doxorubicin—ovarian cancer	7.29e-05	0.000261	CcSEcCtD
Leflunomide—Gastrointestinal pain—Doxorubicin—ovarian cancer	7.24e-05	0.000259	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	7.21e-05	0.000457	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PPP2R1A—ovarian cancer	7.15e-05	0.000453	CbGpPWpGaD
Leflunomide—Hypersensitivity—Epirubicin—ovarian cancer	7.05e-05	0.000252	CcSEcCtD
Leflunomide—DHODH—Metabolism—PTEN—ovarian cancer	7.04e-05	0.000447	CbGpPWpGaD
Leflunomide—Urticaria—Doxorubicin—ovarian cancer	7.03e-05	0.000251	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—YAP1—ovarian cancer	7.02e-05	0.000445	CbGpPWpGaD
Leflunomide—Abdominal pain—Doxorubicin—ovarian cancer	7e-05	0.00025	CcSEcCtD
Leflunomide—Body temperature increased—Doxorubicin—ovarian cancer	7e-05	0.00025	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—XIAP—ovarian cancer	6.88e-05	0.000436	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	6.86e-05	0.000435	CbGpPWpGaD
Leflunomide—Asthenia—Epirubicin—ovarian cancer	6.86e-05	0.000245	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CA—ovarian cancer	6.85e-05	0.000434	CbGpPWpGaD
Leflunomide—Pruritus—Epirubicin—ovarian cancer	6.77e-05	0.000242	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	6.71e-05	0.000426	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	6.71e-05	0.000426	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	6.71e-05	0.000426	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SMARCA4—ovarian cancer	6.7e-05	0.000425	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	6.68e-05	0.000424	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYTB—ovarian cancer	6.66e-05	0.000422	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	6.6e-05	0.000419	CbGpPWpGaD
Leflunomide—Diarrhoea—Epirubicin—ovarian cancer	6.54e-05	0.000234	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—EREG—ovarian cancer	6.54e-05	0.000415	CbGpPWpGaD
Leflunomide—Hypersensitivity—Doxorubicin—ovarian cancer	6.52e-05	0.000233	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	6.45e-05	0.000409	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD8A—ovarian cancer	6.37e-05	0.000404	CbGpPWpGaD
Leflunomide—Asthenia—Doxorubicin—ovarian cancer	6.35e-05	0.000227	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	6.34e-05	0.000402	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HRAS—ovarian cancer	6.33e-05	0.000402	CbGpPWpGaD
Leflunomide—Dizziness—Epirubicin—ovarian cancer	6.32e-05	0.000226	CcSEcCtD
Leflunomide—Pruritus—Doxorubicin—ovarian cancer	6.26e-05	0.000224	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—PGR—ovarian cancer	6.13e-05	0.000389	CbGpPWpGaD
Leflunomide—Vomiting—Epirubicin—ovarian cancer	6.08e-05	0.000217	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL6—ovarian cancer	6.06e-05	0.000384	CbGpPWpGaD
Leflunomide—Diarrhoea—Doxorubicin—ovarian cancer	6.05e-05	0.000217	CcSEcCtD
Leflunomide—Rash—Epirubicin—ovarian cancer	6.03e-05	0.000216	CcSEcCtD
Leflunomide—Dermatitis—Epirubicin—ovarian cancer	6.02e-05	0.000215	CcSEcCtD
Leflunomide—Headache—Epirubicin—ovarian cancer	5.99e-05	0.000214	CcSEcCtD
Leflunomide—Dizziness—Doxorubicin—ovarian cancer	5.85e-05	0.000209	CcSEcCtD
Leflunomide—ABCG2—Metabolism—BRIP1—ovarian cancer	5.82e-05	0.000369	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPP1CC—ovarian cancer	5.82e-05	0.000369	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PARP1—ovarian cancer	5.7e-05	0.000361	CbGpPWpGaD
Leflunomide—Nausea—Epirubicin—ovarian cancer	5.68e-05	0.000203	CcSEcCtD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	5.64e-05	0.000358	CbGpPWpGaD
Leflunomide—Vomiting—Doxorubicin—ovarian cancer	5.63e-05	0.000201	CcSEcCtD
Leflunomide—Rash—Doxorubicin—ovarian cancer	5.58e-05	0.0002	CcSEcCtD
Leflunomide—Dermatitis—Doxorubicin—ovarian cancer	5.57e-05	0.000199	CcSEcCtD
Leflunomide—Headache—Doxorubicin—ovarian cancer	5.54e-05	0.000198	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	5.39e-05	0.000342	CbGpPWpGaD
Leflunomide—Nausea—Doxorubicin—ovarian cancer	5.26e-05	0.000188	CcSEcCtD
Leflunomide—CYP2C9—Metabolism—NME2—ovarian cancer	5.22e-05	0.000331	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TLR4—ovarian cancer	5.2e-05	0.000329	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	5.1e-05	0.000323	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6ST—ovarian cancer	4.98e-05	0.000316	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PIK3CA—ovarian cancer	4.97e-05	0.000315	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PPP2R1A—ovarian cancer	4.62e-05	0.000293	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NME2—ovarian cancer	4.46e-05	0.000283	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	4.43e-05	0.000281	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDH1—ovarian cancer	4.41e-05	0.000279	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CD—ovarian cancer	4.21e-05	0.000267	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKT1—ovarian cancer	4.06e-05	0.000257	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—YAP1—ovarian cancer	3.9e-05	0.000248	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.78e-05	0.00024	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ERBB2—ovarian cancer	3.72e-05	0.000236	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TERT—ovarian cancer	3.67e-05	0.000233	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MTOR—ovarian cancer	3.67e-05	0.000233	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CB—ovarian cancer	3.67e-05	0.000233	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	3.61e-05	0.000229	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1B—ovarian cancer	3.44e-05	0.000218	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CAV1—ovarian cancer	3.4e-05	0.000215	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL2—ovarian cancer	3.37e-05	0.000214	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYTB—ovarian cancer	3.36e-05	0.000213	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	3.29e-05	0.000208	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ESR1—ovarian cancer	3.27e-05	0.000208	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CTNNB1—ovarian cancer	3.25e-05	0.000206	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6ST—ovarian cancer	3.22e-05	0.000204	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—FASN—ovarian cancer	3.18e-05	0.000202	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTEN—ovarian cancer	3.17e-05	0.000201	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC5A5—ovarian cancer	3.13e-05	0.000198	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APC—ovarian cancer	3.09e-05	0.000196	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CG—ovarian cancer	3.09e-05	0.000196	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	3.08e-05	0.000196	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC2A1—ovarian cancer	3.02e-05	0.000192	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPP1CC—ovarian cancer	2.94e-05	0.000186	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—BRIP1—ovarian cancer	2.94e-05	0.000186	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP1B1—ovarian cancer	2.9e-05	0.000184	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYTB—ovarian cancer	2.87e-05	0.000182	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—STAT3—ovarian cancer	2.83e-05	0.00018	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NRAS—ovarian cancer	2.83e-05	0.000179	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.81e-05	0.000178	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CD—ovarian cancer	2.72e-05	0.000172	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK3—ovarian cancer	2.71e-05	0.000172	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK1—ovarian cancer	2.58e-05	0.000163	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—ovarian cancer	2.58e-05	0.000163	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPP2R1A—ovarian cancer	2.57e-05	0.000163	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPP1CC—ovarian cancer	2.51e-05	0.000159	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—BRIP1—ovarian cancer	2.51e-05	0.000159	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KRAS—ovarian cancer	2.43e-05	0.000154	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ERBB2—ovarian cancer	2.4e-05	0.000152	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ABCB1—ovarian cancer	2.39e-05	0.000151	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MTOR—ovarian cancer	2.37e-05	0.00015	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CB—ovarian cancer	2.37e-05	0.00015	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TYMS—ovarian cancer	2.34e-05	0.000149	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL8—ovarian cancer	2.28e-05	0.000144	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CA—ovarian cancer	2.24e-05	0.000142	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1B—ovarian cancer	2.23e-05	0.000141	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CASP3—ovarian cancer	2.18e-05	0.000138	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2—ovarian cancer	2.18e-05	0.000138	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.14e-05	0.000136	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCND1—ovarian cancer	2.12e-05	0.000135	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CTNNB1—ovarian cancer	2.1e-05	0.000133	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HRAS—ovarian cancer	2.07e-05	0.000131	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—ovarian cancer	2.06e-05	0.000131	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTEN—ovarian cancer	2.05e-05	0.00013	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6—ovarian cancer	1.98e-05	0.000126	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—YAP1—ovarian cancer	1.97e-05	0.000125	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.95e-05	0.000124	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CAV1—ovarian cancer	1.89e-05	0.00012	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—ovarian cancer	1.85e-05	0.000117	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STAT3—ovarian cancer	1.83e-05	0.000116	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.83e-05	0.000116	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NRAS—ovarian cancer	1.83e-05	0.000116	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—ovarian cancer	1.83e-05	0.000116	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK3—ovarian cancer	1.75e-05	0.000111	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CG—ovarian cancer	1.72e-05	0.000109	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.72e-05	0.000109	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—ovarian cancer	1.7e-05	0.000108	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—YAP1—ovarian cancer	1.68e-05	0.000107	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.67e-05	0.000106	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK1—ovarian cancer	1.67e-05	0.000106	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—ovarian cancer	1.67e-05	0.000106	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—FASN—ovarian cancer	1.61e-05	0.000102	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC5A5—ovarian cancer	1.58e-05	0.0001	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KRAS—ovarian cancer	1.57e-05	9.98e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC2A1—ovarian cancer	1.53e-05	9.68e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CD—ovarian cancer	1.51e-05	9.59e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.5e-05	9.48e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.47e-05	9.29e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP1B1—ovarian cancer	1.46e-05	9.28e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CA—ovarian cancer	1.45e-05	9.17e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—ovarian cancer	1.4e-05	8.87e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—FASN—ovarian cancer	1.37e-05	8.71e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC5A5—ovarian cancer	1.35e-05	8.57e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HRAS—ovarian cancer	1.34e-05	8.48e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CB—ovarian cancer	1.32e-05	8.36e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC2A1—ovarian cancer	1.3e-05	8.27e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	1.3e-05	8.23e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.29e-05	8.19e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6—ovarian cancer	1.28e-05	8.12e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.28e-05	8.1e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP1B1—ovarian cancer	1.25e-05	7.93e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCB1—ovarian cancer	1.21e-05	7.64e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TYMS—ovarian cancer	1.18e-05	7.51e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—ovarian cancer	1.18e-05	7.49e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTEN—ovarian cancer	1.14e-05	7.22e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.11e-05	7.03e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.1e-05	7e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCB1—ovarian cancer	1.03e-05	6.53e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TYMS—ovarian cancer	1.01e-05	6.42e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CAV1—ovarian cancer	9.54e-06	6.05e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.11e-06	5.78e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CG—ovarian cancer	8.69e-06	5.51e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CAV1—ovarian cancer	8.15e-06	5.17e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CA—ovarian cancer	8.04e-06	5.1e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.79e-06	4.94e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CD—ovarian cancer	7.64e-06	4.84e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CG—ovarian cancer	7.43e-06	4.71e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CB—ovarian cancer	6.66e-06	4.22e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—ovarian cancer	6.57e-06	4.16e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CD—ovarian cancer	6.53e-06	4.14e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTEN—ovarian cancer	5.75e-06	3.65e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CB—ovarian cancer	5.69e-06	3.61e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTEN—ovarian cancer	4.92e-06	3.12e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CA—ovarian cancer	4.06e-06	2.57e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CA—ovarian cancer	3.47e-06	2.2e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—ovarian cancer	3.32e-06	2.1e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—ovarian cancer	2.83e-06	1.8e-05	CbGpPWpGaD
